EGFR and lung carcinoma: Furthermore, we found that resistant populations lose SOX2, a squamous lineage-dependent transcription factor, and upregulated AXL, a tyrosine kinase receptor, whose activity has been shown to promote resistance to EGFR-targeted therapy in lung cancer, in association with EMT transition (Fig. 2d)24, 25.